{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:34:23Z","timestamp":1717806863567},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Chongqing, China","award":["No. cstc2019jcyj-msxmX0422"],"award-info":[{"award-number":["No. cstc2019jcyj-msxmX0422"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Abnormally expressed BCR\/ABL protein serves as the basis for the development of chronic myeloid leukaemia (CML). The F-actin binding domain (FABD), which is a crucial region of the BCR\/ABL fusion protein, is also located at the carboxyl end of the c-ABL protein and regulates the kinase activity of c-ABL. However, the precise function of this domain in BCR\/ABL remains uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The FABD-deficient adenovirus vectors Ad-BCR\/ABL\u25b3FABD, wild-type Ad-BCR\/ABL and the control vector Adtrack were constructed, and 32D cells were infected with these adenoviruses separately. The effects of FABD deletion on the proliferation and apoptosis of 32D cells were evaluated by a CCK-8 assay, colony formation assay, flow cytometry and DAPI staining. The levels of phosphorylated BCR\/ABL, p73, and their downstream signalling molecules were detected by western blot. The intracellular localization and interaction of BCR\/ABL with the cytoskeleton-related protein F-actin were identified by immunofluorescence and co-IP. The effect of FABD deletion on BCR\/ABL carcinogenesis in vivo was explored in CML-like mouse models. The degree of leukaemic cell infiltration was observed by Wright\u2012Giemsa staining and haematoxylin and eosin (HE) staining.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We report that the loss of FABD weakened the proliferation-promoting ability of BCR\/ABL, accompanied by the downregulation of BCR\/ABL downstream signals. Moreover, the deletion of FABD resulted in a change in the localization of BCR\/ABL from the cytoplasm to the nucleus, accompanied by an increase in cell apoptosis due to the upregulation of p73 and its downstream proapoptotic factors. Furthermore, we discovered that the absence of FABD alleviated leukaemic cell infiltration induced by BCR\/ABL in mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings reveal that the deletion of FABD diminished the carcinogenic potential of BCR\/ABL both in vitro and in vivo. This study provides further insight into the function of the FABD domain in BCR\/ABL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12964-024-01694-8","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:01:52Z","timestamp":1717747312000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The FABD domain is critical for the oncogenicity of BCR\/ABL in chronic myeloid leukaemia"],"prefix":"10.1186","volume":"22","author":[{"given":"Renren","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suotian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zesong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"10314","key":"1694_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326.","journal-title":"Lancet"},{"key":"1694_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-Targeted therapies. Cancer Cell. 2020;37:530\u201342.","journal-title":"Cancer Cell"},{"key":"1694_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277\u201380.","journal-title":"Nature"},{"key":"1694_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cncr.31835","volume":"125","author":"AJ Klil-Drori","year":"2019","unstructured":"Klil-Drori AJ, Yin H, Azoulay L, et al. Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. Cancer. 2019;125:618\u201325.","journal-title":"Cancer"},{"key":"1694_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"1694_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","volume":"34","author":"R Kinstrie","year":"2020","unstructured":"Kinstrie R, Horne GA, Morrison H, et al. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia. 2020;34:1613\u201325.","journal-title":"Leukemia"},{"key":"1694_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/blood-2014-07-585943","volume":"124","author":"P Valent","year":"2014","unstructured":"Valent P. Targeting the JAK2-STAT5 pathway in CML. Blood. 2014;124:1386\u20138.","journal-title":"Blood"},{"key":"1694_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and bcr-abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5:33\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1694_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2159-8290.CD-13-0235","volume":"4","author":"J Asmussen","year":"2014","unstructured":"Asmussen J, Lasater EA, Tajon C, et al. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov. 2014;4:200\u201315.","journal-title":"Cancer Discov"},{"key":"1694_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/leu.2009.49","volume":"23","author":"R Naughton","year":"2009","unstructured":"Naughton R, Quiney C, Turner SD, et al. Bcr-abl-mediated redox regulation of the PI3K\/AKT pathway. Leukemia. 2009;23:1432\u201340.","journal-title":"Leukemia"},{"key":"1694_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"1694_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247\u2013306.","journal-title":"Annu Rev Immunol"},{"key":"1694_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1694_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H de Lavallade","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"1694_CR15","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2016.66","volume":"30","author":"W Huang","year":"2016","unstructured":"Huang W, Luan CH, Hjort EE, et al. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Leukemia. 2016;30:1502\u20139.","journal-title":"Leukemia"},{"key":"1694_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309\u201318.","journal-title":"Blood"},{"issue":"3","key":"1694_CR17","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"F Mahon","year":"2000","unstructured":"Mahon F. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070\u20139.","journal-title":"Blood"},{"key":"1694_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015;125:915\u201323.","journal-title":"Blood"},{"key":"1694_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molcel.2005.06.030","volume":"19","author":"O Hantschel","year":"2005","unstructured":"Hantschel O, Wiesner S, G\u00fcttler T, et al. Structural basis for the cytoskeletal association of Bcr-Abl\/c-Abl. Mol Cell. 2005;19:461\u201373.","journal-title":"Mol Cell"},{"key":"1694_CR20","doi-asserted-by":"publisher","first-page":"27104","DOI":"10.1074\/jbc.M100559200","volume":"276","author":"PJ Woodring","year":"2001","unstructured":"Woodring PJ, Hunter T, Wang JY. Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem. 2001;276:27104\u201310.","journal-title":"J Biol Chem"},{"key":"1694_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1083\/jcb.200110014","volume":"156","author":"PJ Woodring","year":"2002","unstructured":"Woodring PJ, Litwack ED, O\u2019Leary DDM, et al. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol. 2002;156:879\u201392.","journal-title":"J Cell Biol"},{"key":"1694_CR22","doi-asserted-by":"publisher","first-page":"D503","DOI":"10.1093\/nar\/gkx1021","volume":"46","author":"M Bernhofer","year":"2018","unstructured":"Bernhofer M, Goldberg T, Wolf S, et al. NLSdb-major update for database of nuclear localization signals and nuclear export signals. Nucleic Acids Res. 2018;46:D503\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1694_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2008.03.074","volume":"135","author":"J Qian","year":"2008","unstructured":"Qian J, Sarnaik AA, Bonney TM, et al. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology. 2008;135:152\u201362.","journal-title":"Gastroenterology"},{"key":"1694_CR24","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1073\/pnas.95.13.7457","volume":"95","author":"S Taagepera","year":"1998","unstructured":"Taagepera S, McDonald D, Loeb JE, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A. 1998;95:7457\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1694_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI116786","volume":"92","author":"M Wetzler","year":"1993","unstructured":"Wetzler M, Talpaz M, Van Etten RA, et al. Subcellular localization of bcr, Abl, and bcr-abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest. 1993;92:1925\u201339.","journal-title":"J Clin Invest"},{"key":"1694_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41413-020-0095-2","volume":"8","author":"CL Schwebach","year":"2020","unstructured":"Schwebach CL, Kudryashova E, Zheng W, et al. Osteogenesis Imperfecta mutations in plastin 3 lead to impaired calcium regulation of actin bundling. Bone Res. 2020;8:21.","journal-title":"Bone Res"},{"key":"1694_CR27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/j.1460-2075.1996.tb00503.x","volume":"15","author":"ST Wen","year":"1996","unstructured":"Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and rb tumor suppressor gene products. EMBO J. 1996;15:1583\u201395.","journal-title":"EMBO J"},{"key":"1694_CR28","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nprot.2007.135","volume":"2","author":"J Luo","year":"2007","unstructured":"Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007;2:1236\u201347.","journal-title":"Nat Protoc"},{"key":"1694_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jgm.543","volume":"6","author":"M Nilsson","year":"2004","unstructured":"Nilsson M, Ljungberg J, Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med. 2004;6:631\u201341.","journal-title":"J Gene Med"},{"key":"1694_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li S, Ilaria RL, Million RP, et al. The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399\u2013412.","journal-title":"J Exp Med"},{"key":"1694_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33:1173\u201383.","journal-title":"Leukemia"},{"issue":"5","key":"1694_CR32","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2021","unstructured":"Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2021;118(5):1208\u201315.","journal-title":"Blood"},{"key":"1694_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/leu.2010.257","volume":"25","author":"H Modi","year":"2011","unstructured":"Modi H, Li L, Chu S, et al. Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia. 2011;25:305\u201312.","journal-title":"Leukemia"},{"key":"1694_CR34","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1242\/dev.093831","volume":"140","author":"MP O\u2019Donnell","year":"2013","unstructured":"O\u2019Donnell MP, Bashaw GJ. Distinct functional domains of the Abelson tyrosine kinase control axon guidance responses to Netrin and Slit to regulate the assembly of neural circuits. Development. 2013;140:2724\u201333.","journal-title":"Development"},{"key":"1694_CR35","doi-asserted-by":"publisher","first-page":"14865","DOI":"10.1073\/pnas.251249298","volume":"98","author":"Y Wang","year":"2001","unstructured":"Wang Y, Miller AL, Mooseker MS, et al. The abl-related gene (arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin. Proc Natl Acad Sci U S A. 2001;98:14865\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1694_CR36","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0301-472X(99)00084-3","volume":"27","author":"R Bhatia","year":"1999","unstructured":"Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol. 1999;27:1384\u201396.","journal-title":"Exp Hematol"},{"key":"1694_CR37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.ejcb.2012.04.006","volume":"91","author":"T Daubon","year":"2012","unstructured":"Daubon T, Rochelle T, Bourmeyster N, et al. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells. Eur J Cell Biol. 2012;91:978\u201387.","journal-title":"Eur J Cell Biol"},{"key":"1694_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cell.2016.05.077","volume":"166","author":"SD Cappell","year":"2016","unstructured":"Cappell SD, Chung M, Jaimovich A, et al. Irreversible APC(Cdh1) inactivation underlies the point of no return for cell-cycle entry. Cell. 2016;166:167\u201380.","journal-title":"Cell"},{"key":"1694_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228\u201334.","journal-title":"Nat Med"},{"key":"1694_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.onc.1202407","volume":"18","author":"PA Skourides","year":"1999","unstructured":"Skourides PA, Perera SA, Ren R. Polarized distribution of bcr-abl in migrating myeloid cells and co-localization of bcr-abl and its target proteins. Oncogene. 1999;18:1165\u201376.","journal-title":"Oncogene"},{"key":"1694_CR41","doi-asserted-by":"crossref","unstructured":"Antonenko SV, Telegeev GD. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of bcr-abl level in K562 cells. Exp Oncol. 2020;42.","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14533"},{"key":"1694_CR42","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1093\/nar\/gkz055","volume":"47","author":"F Wienholz","year":"2019","unstructured":"Wienholz F, Zhou D, Turkyilmaz Y, et al. FACT subunit Spt16 controls UVSSA recruitment to lesion-stalled RNA Pol II and stimulates TC-NER. Nucleic Acids Res. 2019;47:4011\u201325.","journal-title":"Nucleic Acids Res"},{"key":"1694_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00005-011-0126-1","volume":"59","author":"T Akiyama","year":"2011","unstructured":"Akiyama T, Tanaka S. Bim: guardian of tissue homeostasis and critical regulator of the immune system, tumorigenesis and bone biology. Arch Immunol Ther Exp (Warsz). 2011;59:277\u201387.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"1694_CR44","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1172\/JCI99217","volume":"128","author":"D Feng","year":"2018","unstructured":"Feng D, Amgalan D, Singh R, et al. SNAP23 regulates BAX-dependent adipocyte programmed cell death independently of canonical macroautophagy. J Clin Invest. 2018;128:3941\u201356.","journal-title":"J Clin Invest"},{"issue":"3","key":"1694_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1535-6108(04)00056-X","volume":"5","author":"D Jamil","year":"2004","unstructured":"Jamil D, Raia D, Martin C. BCR\/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell. 2004;5(3):275\u201385.","journal-title":"Cancer Cell"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-01694-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:12:16Z","timestamp":1717747936000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01694-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-01694-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"20 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study met the standards of the Declaration of Helsinki and was approved by the Ethics Committee of Chongqing Medical University <b>(Approval No. 2022062).<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}